1,025 followers
RT @doctorC369: This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
3,420 followers
RT @doctorC369: This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
28 followers
RT @doctorC369: This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
1,025 followers
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
4,780 followers
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
902 followers
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
1,025 followers
RT @btfoundation: Dr. Daniel Catenacci @DocCatenacci from @UChicagoMed is speaking about gastroesophageal #Cancer THIS Sunday at our #GICan…
1,025 followers
This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
3,420 followers
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
4,053 followers
If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna1024 @agrothey @GABOUALFA @AmanChauhanMD @JoeChaoMD @doctorC369 @SirohiBhawna @EileenMOReilly. If questions, contact Sam sam.m@binay
3,420 followers
Dr. Daniel Catenacci @DocCatenacci from @UChicagoMed is speaking about gastroesophageal #Cancer THIS Sunday at our #GICancer #GISM conference! Register at https://t.co/q1BVbJWvwY Check out some projects he's contributed to: 1. https://t.co/Ik0x7ABXqK 2.
11,981 followers
Dr. Charles Fuchs et al found, "Pembrolizumab demonstrated antitumor activity & was well tolerated as monotherapy & in combo w/ chemo in patients w/ previously untreated advanced gastric junction adenocarcinoma." https://t.co/PHIONgaAcT @YaleMed @C
2,602 followers
RT @polom_karol: #Pembrolizumab in #gastriccaner #KEYNOTE059 phase2 study. safety profile. good response rate promising #molecular treatmen…
80 followers
RT @polom_karol: #Pembrolizumab in #gastriccaner #KEYNOTE059 phase2 study. safety profile. good response rate promising #molecular treatmen…
1,232 followers
#Pembrolizumab in #gastriccaner #KEYNOTE059 phase2 study. safety profile. good response rate promising #molecular treatment @SpringerSurgery https://t.co/J4wnghzWtl